Intracellular iron homeostasis-regulated epigenetic reprogramming contributes to -7/del(7q) leukemia.
A newly discovered iron-control mechanism in blood cancers opens a previously hidden route for treatment development.
A CRISPR screen in haematopoietic stem and progenitor cells identified ABCB8, a mitochondrial iron transporter located on 7q, as essential for myeloid differentiation; its loss accelerates leukemogenesis in mice by reducing cytoplasmic iron, impairing the histone demethylase KDM6A, and increasing repressive H3K27me3 marks. This reveals an iron–epigenetic axis as a previously unknown tumour suppressor mechanism in the most clinically aggressive chromosomal deletion in AML.
What the study was
- Study design
- mechanistic_preclinical
- Category
- hematologic_malignancies
- Maturity
- Exploratory
- Journal
- Nat Commun
Why it surfaced
Nature Communications; mechanistically novel discovery implicating iron homeostasis in epigenetic regulation of del7q AML; design_quality/population/applicability capped as purely preclinical with no human clinical data or therapeutic readout; high basic science interest but limited near-term clinical translation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.